Journey Colab

Psychedelic medicine developer

Journey Colab is a psychedelic medicine developer focused on synthetic mescaline hydrochloride, including its candidate JOUR-5700 for alcohol use disorder. The supplied pipeline information lists JOUR-5700 as preclinical; a source mentions a planned FDA-authorized Phase 2 trial with All Points North, but a confirmed clinical start is not established. The sources do not confirm an ownership change or a completed clinical-development milestone in 2025 or 2026. The company is listed in San Francisco, California, and its candidates are investigational and not available to buy.

Website

journeycolab.com

Journey Colab catalog

All products · Psychedelic medicine pipeline

Shop the Journey Colab catalog

1 item across 1 shelf

Psychedelic medicine pipeline1 item

• JOUR-5700 – Synthetic mescaline hydrochlorideInvestigational